Adagene (NASDAQ:ADAG) CEO Peter Luo Purchases 20,290 Shares

Posted by Stanley Muller on Sep 18th, 2026

Adagene Inc. Sponsored ADR (NASDAQ:ADAG – Get Free Report) CEO Peter Luo acquired 20,290 shares of Adagene stock in a transaction dated Wednesday, September 16th. The stock was purchased at an average price of $3.15 per share, with a total value of $63,913.50. Following the completion of the purchase, the chief executive officer directly owned 88,535 shares of the company’s stock, valued at $278,885.25. The trade was a 29.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter Luo also recently made the following trade(s):

On Wednesday, August 5th, Peter Luo acquired 279 shares of Adagene stock. The shares were purchased at an average cost of $3.65 per share, with a total value of $1,018.35.
On Tuesday, August 4th, Peter Luo bought 22,966 shares of Adagene stock. The stock was purchased at an average price of $3.65 per share, for a total transaction of $83,825.90.

Adagene Trading Up 6.3%

Shares of ADAG opened at $3.37 on Friday. Adagene Inc. Sponsored ADR has a one year low of $1.30 and a one year high of $4.85. The company has a current ratio of 5.02, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $3.68 and its 200 day moving average price is $3.73.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Adagene stock. Fifth Lane Capital LP increased its position in shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG – Free Report) by 427.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 145,000 shares of the company’s stock after buying an additional 117,500 shares during the quarter. Fifth Lane Capital LP owned 0.31% of Adagene worth $274,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.51% of the company’s stock.

More Adagene News

Here are the key news stories impacting Adagene this week:

Positive Sentiment: CEO Peter Luo purchased 20,290 shares at an average price of $3.15, investing approximately $63,914 and increasing his direct ownership by nearly 30%. The transaction may signal management confidence in Adagene’s long-term prospects. SEC insider purchase filing
Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $7.00 price target, implying substantial upside relative to recent trading levels. The analyst raised projected EPS for 2027 through 2030, with expected losses improving to $0.42 per share in 2027, $0.70 in 2028, $1.07 in 2029 and $0.87 in 2030. Adagene earns Buy rating from HC Wainwright
Positive Sentiment: At the H.C. Wainwright conference, Adagene highlighted its high-dose CTLA-4 therapy, keeping investor attention focused on its immuno-oncology pipeline and potential clinical catalysts. Adagene conference presentation
Neutral Sentiment: The earnings revisions were not uniformly positive: HC Wainwright lowered its FY2026 loss estimate to $0.43 per share from $0.37, while maintaining improving loss forecasts for later years. Adagene’s continuing projected losses and early-stage drug-development risk remain important concerns.

Analyst Ratings Changes

ADAG has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Adagene in a research note on Monday. Chardan Capital initiated coverage on Adagene in a report on Thursday, September 10th. They issued a “buy” rating and a $9.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Adagene in a research report on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adagene in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Read Our Latest Research Report on Adagene

Adagene Company Profile

(Get Free Report)

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene’s technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.